Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes by Tahrani, Abd A. & Barnett, Anthony H.
Abd A. Tahrani () · Anthony H. Barnett 
Heart of England NHS Foundation Trust, 
Birmingham Heartlands Hospital, 
Bordesley Green East, Birmingham B9 5SS, UK and 
University of Birmingham, Birmingham, UK. 
Email: a.a.tahrani@bham.ac.uk
Diabetes Ther (2010)  1(2):45-56.
DOI 10.1007/s13300-010-0007-3
REVIEW
Dapagliflozin: a Sodium Glucose Cotransporter 2 Inhibitor 
in Development for Type 2 Diabetes
Abd A. Tahrani · Anthony H. Barnett
Received: August 4, 2010 / Published online: January 19, 2011
© The Author(s) 2010. This article is published with open access at Springerlink.com
ABSTRACT
Type 2 diabetes mellitus (T2DM) is a growing 
worldwide  epidemic.  Patients  face  lifelong 
therapy to control hyperglycemia and prevent 
the associated complications. There are many 
medications, with varying mechanisms, available 
for the treatment of T2DM, but almost all target the 
declining insulin sensitivity and secretion that are 
associated with disease progression. Medications 
with such insulin-dependent mechanisms of 
action often lose efficacy over time, and there is 
increasing interest in the development of new 
antidiabetes medications that are not dependent 
upon insulin. One such approach is through the 
inhibition of renal glucose reuptake. Dapagliflozin, 
the first of a class of selective sodium glucose 
cotransporter 2 inhibitors, reduces renal glucose 
reabsorption and is currently under development 
for the treatment of T2DM. Here, we review the 
literature relating to the preclinical and clinical 
development of dapagliflozin.
Keywords:  dapagliflozin;  diabetes;  SGLT2 
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INTRODUCTION
More than 285 million people worldwide have 
diabetes and this number is estimated to climb 
to 438 million by 2030.1 Type 2 diabetes mellitus 
(T2DM) is the most common form, accounting 
for approximately 85% of all cases.2 
T2DM is a progressive disorder characterized 
by hyperglycemia, peripheral insulin resistance 
(in  most  cases),  and  a  decrease  in  insulin 
secretion.3,4 Development of T2DM is a lengthy 
multistage  process  and  changes  in  insulin 
resistance, insulin secretion, and plasma glucose 
can be present many years before a diagnosis of 
T2DM is made.5 Increasing insulin resistance 
(reduced  sensitivity  of  tissues  to  insulin) 
generally occurs as the first in this sequence 
of events and is followed by a compensatory 
increase in insulin secretion by the pancreatic 
beta-cells, thereby maintaining close to normal 
plasma glucose levels.4,6 In those individuals 
who ultimately develop T2DM a combination of 
beta-cell dysfunction and a reduction in beta-cell 
mass culminates in decreasing insulin secretion 
and  associated  hyperglycemia.  By  the  time 46 Diabetes Ther (2010)  1(2):45-56.
T2DM is diagnosed 50% of the beta-cell function 
may already be lost.7 In addition, excessive and 
inappropriate glucagon secretion is commonly 
observed in T2DM, which might exacerbate 
hyperglycemia and complicate management of 
the disorder.8
As a result of the deleterious effects of chronic 
hyperglycemia  the  majority  of  individuals 
with  T2DM  will  experience  microvascular 
and/or  macrovascular  complications.  These 
include  diabetic  retinopathy,  nephropathy, 
neuropathy, peripheral arterial disease, stroke, 
and coronary artery disease.9  The  ultimate 
goal of any pharmacological intervention in 
T2DM is to limit microvascular and potentially 
macrovascular complications by maintaining 
plasma glucose levels within a relatively normal 
range.10 This link between glycemic control 
and vascular complications was highlighted in 
the UK Prospective Diabetes Study (UKPDS). 
Glycated hemoglobin A1c (HbA1c) levels were 
used as a determinant of glycemic control, and 
for every 1% reduction in HbA1c it was estimated 
that there would be an associated 37% risk 
reduction for microvascular complications and 
a 21% reduction in diabetes-related deaths.11
CURRENTLY AVAILABLE 
TREATMENTS
There is a well-established association between 
weight gain and T2DM, and the majority of 
T2DM patients are overweight or obese. While 
in some countries treatment of T2DM often 
begins with the introduction of medications 
in addition to lifestyle modification, in others 
lifestyle changes are the first course of treatment 
implemented  and  are  aimed  at  restoring 
glycemic control through diet modification 
and  the  introduction  of  a  regular  exercise 
program. However, most patients will be unable 
to maintain normoglycemia for any length of 
time without pharmacological intervention. 
Furthermore, due to the progressive nature of 
T2DM, an intensification of this initial treatment 
is often required to maintain glycemic control. 
This can involve the escalation of medication 
dosage  and/or  the  inclusion  of  additional 
antidiabetes  medications  into  the  ongoing 
treatment plan. A wide choice of antidiabetes 
medications  are  available,  the  majority  of 
which target the increasing insulin resistance 
or decreasing insulin secretion and are listed 
below.
•	 Metformin	is	generally	recommended	as	the	
first line of treatment in T2DM. It decreases 
hepatic  glucose  production,  improves 
glucose clearance through an improvement 
of hepatic insulin sensitivity, decreases fatty 
acid oxidation, and increases glucagon-like 
peptide 1 (GLP-1; an endogenous peptide 
secreted from the gastrointestinal tract and 
a potent stimulator of glucose-dependent 
insulin release) levels.12-15 
•	 Sulfonylureas,	 such	 as	 glimepiride	 and	
glipizide, inhibit pancreatic beta-cell KATP 
channels and enhance insulin secretion.16 
•	 Thiazolidinediones	 (TZDs),	 such	 as	
rosiglitazone  and  pioglitazone,  are 
peroxisome proliferator-activated receptor-
gamma agonists. They increase the sensitivity 
of muscle, fat, and liver to endogenous and 
exogenous insulin indirectly reducing hepatic 
glucose production by altering adipose tissue 
lipid metabolism.13 
•	 Meglitinides,	 such	 as	 repaglinide	 and	
nateglinide, also bind to the beta-cell KATP 
channel,  albeit  at  a  different  site,  and 
stimulate insulin secretion.17 
•	 GLP-1	mimetics,	including	exenatide	and	
liraglutide, bind to GLP-1 receptors at several 
sites including pancreatic beta-cells.18 They 
potentiate meal-related glucose-dependent 
insulin secretion and glucagon suppression Diabetes Ther (2010)  1(2):45-56. 47
and  delay  gastric  emptying  resulting  in 
reduced  postprandial  hepatic  glucose 
production and enhanced peripheral glucose 
uptake.19 
•	 Dipeptidyl	peptidase-4	(DPP-4)	inhibitors,	
such  as  sitagliptin,  vildagliptin,  and 
saxagliptin,  prevent  the  degradation  of 
endogenous GLP-1, thereby prolonging its 
insulinotropic activity.20,21 
•	 Amylin	 mimetics	 (eg,	 pramlintide)	 are	
synthetic analogs of the beta-cell hormone 
amylin.22  They  act  by  slowing  down  the 
movement of food through the intestine and 
the absorption of glucose from the intestine, 
reducing postprandial glucose levels. Amylin 
mimetics also inhibit postprandial glucagon 
production.16 
•	 The	 alpha-glucosidase	 inhibitors,	 such	
as acarbose, are one of the few classes of 
antidiabetes  agents  that  do  not  have  an 
insulin-dependent  mechanism  of  action. 
They  act  by  reducing  the  breakdown  of 
oligosaccharides to monosaccharides in the 
proximal small intestine, thereby lowering 
postprandial glucose levels.16 
•	 Insulin	treatment	provides	glycemic	control	
through direct stimulation of the insulin 
receptor.16 
With the continual decline in insulin secretion 
and sensitivity that occurs as T2DM progresses, 
medications that rely upon those mechanisms 
for their activity frequently lose efficacy and, 
despite  the  availability  of  several  different 
classes of antidiabetic agents, up to 60% of 
T2DM patients still do not achieve their target 
glycemic goals.23 There is a need, therefore, for 
orally active antidiabetes medications that act 
via insulin-independent mechanisms. One such 
approach currently under clinical investigation is 
through inhibition of renal glucose reabsorption 
and the consequent enhancement of urinary 
glucose excretion.
RENAL GLUCOSE REABSORPTION 
AND SODIUM GLUCOSE 
COTRANSPORTER 2 (SGLT2) 
INHIBITORS
The  role  of  the  kidneys  in  maintaining 
normoglycemia,  through  the  filtration  and 
reabsorption of glucose as well as gluconeogenesis, 
is well established. Every day 180 L of plasma 
are  filtered  through  the  kidneys  and,  in 
normoglycemic individuals, this translates to 
approximately 180 g of glucose.24,25 Under normal 
conditions the ability of the kidneys to reabsorb 
glucose from the glomerular filtrate is extremely 
effective, with less than 0.5 g/day of this filtered 
glucose ultimately appearing in the urine. Under 
periods of hyperglycemia the amount of filtered 
glucose reabsorbed increases in proportion to 
the plasma glucose concentration until the 
resorptive capacity of the tubules is exceeded, 
at which point the excess glucose is excreted in 
urine (glucosuria).26 
Glucose reabsorption in the renal tubules is 
accomplished by way of SGLTs that move glucose 
into the renal epithelial cells. The majority of 
the glucose is reabsorbed from the glomerular 
filtrate by SGLT2.24 SGLT2 is a high-capacity, 
low-affinity transporter predominantly expressed 
in the kidney where it is exclusively found in 
the brush border membrane of the S1 segment 
of the proximal tubule.25,27,28 The remainder 
of the glucose is reabsorbed from the filtrate 
in the distal S3 segment of the renal proximal 
tubule by the high-affinity, low-capacity glucose 
transporter sodium glucose cotransporter 1, 
SGLT1 (Figure 1A).29,30 However, while SGLT2 
is  predominantly  expressed  in  the  kidney, 
SGLT1 is also highly expressed in the small 
intestine, where it is involved in the transport 
of glucose across the brush border membrane.30 
In the renal tubule an electrochemical gradient 
generated by the Na+/K+ ATPase located in the 48 Diabetes Ther (2010)  1(2):45-56.
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Figure 1. (A) Diagram of a renal tubule illustrating the 
distribution of sodium glucose cotransporter 2 (SGLT2) 
and SGLT1 and the proportion of glucose reabsorption. 
Th   e majority of glucose is reabsorbed through SGLT2 
versus SGLT1. (B) Schematic representation of the renal 
reabsorption of glucose by SGLT1/2. SGLT2 transports 
glucose through the tubular epithelial cells. Glucose 
concentrated inside the cell is then transported across the 
basolateral membrane and into the peritubular capillary 
by glucose transporter 2 (GLUT2). Reproduced with 
permission.
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basolateral membrane drives the movement of 
sodium ions across the luminal membrane and 
provides the driving force for glucose cotransport 
(Figure 1B).24
Increasing urinary glucose excretion through 
an inhibition of glucose reabsorption represents 
an  attractive  method  of  maintaining  blood 
glucose control without the accompanying risk 
of hypoglycemia seen with those antidiabetes 
medications that increase insulin secretion. In 
addition, the caloric loss associated with the 
excreted glucose may be anticipated to cause 
weight loss.
The concept of normalizing glucose levels 
through an increase in urinary glucose excretion 
is  not  a  new  one.  The  antihyperglycemic 
properties of the glucosuric agent phlorizin, an 
SGLT inhibitor derived from apple tree bark, 
have been known for many years. However, 
clinical use of phlorizin was not feasible due to 
nonselectivity. In addition, phlorizin had limited 
oral bioavailability due to the degradation of an 
O-glucoside linkage by gastrointestinal beta-
glucosidases.31,32
In the quest for a more attractive clinical 
candidate  a  number  of  specific  inhibitors 
of  SGLT2  have  been  developed.  Several  are 
undergoing  late  phase  clinical  testing  for 
T2DM, eg dapaglifl  ozin, canaglifl  ozin, ASP1941, 
LX4211, and BI10773.33  Two  further  SGLT2 
inhibitors that displayed promising initial results, 
serglifl  ozin and remoglifl  ozin etabonate, were 
discontinued for a variety of reasons, including 
nonselectivity,  unfavorable  pharmaceutical 
properties,  or  development  of  replacement 
SGLT2 compounds.34-36
Dapaglifl  ozin is furthest along in development 
and is currently in phase 3 trials. For the remainder 
of this article we will review the preclinical and 
clinical data available for dapaglifl  ozin. 
DAPAGLIFLOZIN
Preclinical Studies
In preclinical studies dapagliflozin exhibited 
potent inhibition of human SGLT2 with an EC50 
of 1.1 nM and a 1200-fold selectivity for human 
SGLT2  over  human  SGLT1,  and  contained 
a  beta-glucosidase-resistant  C-glucoside  in 
place of the O-glucoside linkage, permitting 
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oral administration.32,37 In both normal and 
experimentally diabetic rats dapagliflozin induced 
significant renal glucose excretion.37 Normal 
rats exhibited an improved glucose tolerance 
profile with a single dose of dapagliflozin and 
this was associated with reductions in glucose 
excursions  following  oral  glucose  tolerance 
testing (OGTT).37 In two different rat models 
of	diabetes	(streptozotocin	and	Zucker	diabetic	
fatty	[ZDF]	rats)	hyperglycemia	was	reduced	
after administration of a single oral dose of 
dapagliflozin and was observed within 6 hours 
of dosing.32,37 Reductions in both fasting and 
postprandial glucose levels were maintained in 
ZDF	rats	over	2	weeks	with	once-daily	dosing	
with dapagliflozin.37 The promising efficacy, 
tolerability, and overall favorable absorption, 
distribution, metabolism, and excretion profile 
of dapagliflozin led to its clinical evaluation in 
healthy and T2DM subjects.32
Clinical Studies
Pharmacokinetics
Single-ascending  (SAD)  and  multiple-
ascending  (MAD;  2-week  duration)  dose 
studies were performed in healthy and T2DM 
subjects to evaluate the pharmacokinetic and 
pharmacodynamic profile of dapagliflozin (2.5-
500 mg SAD; 2.5-100 mg/day MAD).38,39 After 
oral administration absorption of dapagliflozin 
was  rapid  in  both  healthy  and  T2DM 
participants (Tmax of approximately 1-2 hours). 
It demonstrated a half-life of approximately 
16  to  17  hours  in  both  populations.38,39 
Dapagliflozin is highly protein bound and renal 
excretion was minimal throughout the 2-week 
studies in both populations. Dapagliflozin is 
primarily metabolized via  uridine diphosphate 
glucuronosyltransferase  1-9  (UGT1A9)  to 
form the inactive glucuronidated metabolite, 
dapagliflozin 3-O-glucuronide (BMS-801576), 
which is excreted in the urine.38 Total exposure 
to dapagliflozin was proportional to dose and 
similar on day 1 and day 14 in both healthy 
and T2DM subjects. After 14 days dapagliflozin 
accumulation was minimal and not different 
between  the  healthy  and  T2DM  subjects 
(accumulation index: 1.20-1.30 and 1.23-1.33, 
respectively).38,39 Thus, the pharmacokinetic 
profile of dapagliflozin was consistent with a 
once-daily administration protocol. 
Pharmacodynamics
Renal  glucose  excretion  was  enhanced  by 
dapagliflozin in healthy and T2DM individuals in 
a dose-dependent fashion and reached a plateau 
at the 20 mg/day dose. Following 2 weeks of 
daily dapagliflozin dosing, cumulative amounts 
of urinary glucose ranged from 20 to 55 g/day 
in healthy subjects and from 37 to 70 g/day in 
T2DM patients (Figure 2).38,39 
In two separate 12-week trials once-daily 
dapagliflozin  was  administered  to  T2DM 
participants who were either treatment naïve 
(dapagliflozin 2.5-50 mg once daily)40 or had 
ongoing insulin therapy with insulin sensitizers 
(dapagliflozin 10-20 mg once daily).41 A similar 
Figure 2. Total cumulative amount of glucose excreted 
in the urine over 24 hours from type 2 diabetes mellitus 
patients following 14 days of treatment with either 
dapagliflozin or placebo. A significant increase in urinary 
glucose excretion was seen at all doses plateauing 
at the 25 mg once-daily dose. Reproduced with permission.
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increase in urinary glucose excretion (up to 
approximately 85 g/day) was observed at the 
conclusion of the 12-week treatment period in 
both populations.40,41 
Clinical Efficacy in T2DM Patients
Healthy subjects administered dapagliflozin 
(2.5-100  mg  once  daily)  for  up  to  2  weeks 
exhibited no change in glycemic parameters.38 
However,  T2DM  patients  administered 
dapagliflozin (5-100 mg once daily) over the 
same time period exhibited significant dose-
dependent reductions in fasting serum glucose 
at day 13. In addition, improvements in OGTT 
were also observed on day 13 with all doses of 
dapagliflozin in the T2DM individuals.39
In 12-week studies of once-daily dapagliflozin 
significant reductions in glucose excursions 
were seen in T2DM patients following OGTT, as 
well as dose-proportional reductions in fasting 
plasma glucose. Significant improvements in 
HbA1c levels were also seen with dapagliflozin 
in  T2DM  subjects  over  the  12-week  dosing 
period.40,41 A –0.55% to –0.90% change in HbA1c 
was seen following 12 weeks of dapagliflozin 
treatment (2.5-50 mg once daily) versus –0.18% 
with placebo in treatment-naïve T2DM patients 
(baseline mean HbA1c 7.6% to 8%). Furthermore, 
significantly more patients achieved their target 
glycemic goal of <7% HbA1c with 50 mg once 
daily dapagliflozin (59%) compared with placebo 
(32%) following the 12-week treatment period.40 
In T2DM patients currently receiving insulin 
plus an insulin sensitizer, changes of –0.61% to 
–0.69% in HbA1c (baseline mean 8.3% to 8.5%) 
were observed compared with a mean increase 
of  0.09%  in  the  placebo  group  (Figure  3). 
Around 63% of those subjects achieved a ≥0.5% 
reduction  at  week  12  in  HbA1c  levels  with 
dapagliflozin (10 and 20 mg once daily) versus 
16% in the placebo group.41 This reduction 
in HbA1c in patients inadequately controlled 
on insulin has been shown to be maintained 
following 24 and 48 weeks of dapagliflozin 
treatment.42,43  A  significant  reduction  in 
HbA1c  of  –0.75%  to  –0.90%  (mean  baseline 
HbA1c 8.5%) was observed at 24 weeks with 
dapagliflozin compared with placebo (–0.3%).42 
At 48 weeks a change of –0.74% to –0.94% with 
HbA1c
 (baseline mean approximately 8.5%) was 
recorded with dapagliflozin (2.5-10 mg once 
daily) compared with –0.43% in the placebo 
group.43 Dapagliflozin also reduced the rate of 
insulin uptitration and study discontinuation as 
a result of a lack of glycemic control following 
48 weeks of treatment in patients with T2DM.44 
In comparison, the change in mean HbA1c 
from  baseline  mean  (8.41%)  seen  with  the 
GLP-1 mimetic exenatide in T2DM patients 
inadequately controlled on insulin was –1.71% 
with  exenatide  versus  –1.00%  with  placebo 
Figure 3. Change in mean HbA1c (%) from baseline over 
a 12-week treatment period with either dapagliflozin 
or placebo in type 2 diabetes mellitus subjects with 
ongoing insulin therapy. A significant reduction in HbA1c 
was seen over 12 weeks with 10 and 20 mg once-daily 
dapagliflozin. DAPA=dapagliflozin; HbA1c=hemoglobin 
A1c; INS=insulin; LOCF=last observation carried 
forward; PLA=placebo. Copyright 2009 American Diabetes 
Association. From Diabetes Care, Vol. 32, 2009; 1656-1662. 
Reprinted with permission from The American Diabetes 
Association.
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over 30 weeks.45 Owing to differences between 
the trial designs it is not possible to draw direct 
comparisons between the trials, although it is 
notable that while the reduction in HbA1c with 
exenatide was numerically greater than observed 
with dapagliflozin the reduction in HbA1c in the 
placebo group was also larger than that seen in 
the dapagliflozin trial.
When  administered  for  24  weeks  as  a 
monotherapy to treatment-naïve T2DM patients 
dapagliflozin (2.5-10 mg once daily) produced 
dose-dependent reductions in HbA1c levels from 
a baseline mean of 7.8% to 8.0% that were 
statistically significant with the 5 mg and 10 
mg doses (–0.77% and –0.89%, respectively) 
versus –0.23% with placebo.46 In patients with 
ongoing metformin therapy there was a –0.67% 
to –0.84% change in HbA1c from a baseline 
mean of 7.92% to 8.17% with dapagliflozin 
(2.5-10 mg once daily) at 24 weeks as compared 
with –0.30% in the placebo group.47 Furthermore, 
in a 24-week study evaluating the effectiveness 
of  dapagliflozin  in  patients  with  T2DM 
inadequately controlled on the sulfonylurea 
glimepiride, significant reductions in HbA1c from 
the baseline mean (8.07% to 8.15%) of –0.58% 
to –0.82% with dapagliflozin (2.5-10 mg once 
daily) were observed compared with –0.13% 
with placebo.48
In  the  longest  reported  trial  with 
dapagliflozin  so  far  (52  weeks)  reductions 
in  HbA1c  with  dapagliflozin  from  baseline 
mean  (approximately  7.72%)  were  reported 
in patients poorly controlled with metformin. 
The adjusted mean change from baseline was 
–0.52% with dapagliflozin (≤10 mg once daily) 
compared with a similar reduction of –0.52% 
with the sulfonylurea glipizide after 52 weeks of 
treatment.49
Total body weight loss occurred in all groups 
in the 12-week study in treatment-naïve T2DM 
patients. The reduction in body weight was 
continuous across the dosing period and ranged 
from –2.5% to –3.4% at 12 weeks and –1.2% in 
placebo although this did not reach statistical 
significance.40 After 12 weeks the change in body 
weight with dapagliflozin in T2DM patients 
taking insulin and insulin sensitizers was –4.3 
to –4.5 kg in the dapagliflozin treatment groups 
versus –1.9 kg with placebo (Figure 4).41 Both 
24-week and 48-week studies were consistent 
with this effect of dapagliflozin on weight loss 
(24 weeks: –1.67 kg with 10 mg vs. 0.02 kg 
placebo, P≤0.0001; 48 weeks: –1.79 kg with 
10 mg vs. –0.18 kg).42,43 In treatment-naïve T2DM 
patients, decreases of up to 3.3 kg were observed 
after 24 weeks of treatment with dapagliflozin 
and decreases of 2.2 kg were evident in the 
placebo group, although this was not reported 
as being significant. In metformin-treated T2DM 
patients, reductions of up to 3.0 kg in body 
Figure 4. Changes from baseline in mean body weight 
over 12 weeks of treatment with dapagliflozin (DAPA) 
or placebo (PLA) in subjects with ongoing insulin (INS) 
therapy. A trend towards continuous and greater weight 
loss was seen over 12 weeks with 10 and 20 mg once-daily 
dapagliflozin versus placebo. LOCF=last observation 
carried forward. Copyright 2009 American Diabetes 
Association. From Diabetes Care, Vol. 32, 2009; 1656-1662. 
Reprinted with permission from The American Diabetes 
Association.
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weight were seen with dapagliflozin (2.5-10 mg 
once daily) as compared with 0.9 kg in the 
placebo group following 24 weeks of treatment, 
with similar reductions following 52 weeks of 
treatment.46,47,49
Tolerability and Side Effects
In T2DM patients adverse events observed in the 
dapagliflozin treatment and placebo groups were 
similar in frequency and were generally mild in 
nature whether for patients who were treatment 
naïve or for those receiving ongoing metformin 
or insulin plus insulin sensitizer therapy.40-47 Few 
cases of hypoglycemia were observed and these 
were generally mild, self-limiting, and occurred 
with a similar frequency in the placebo group; 
none were severe.40-47
A mild diuretic effect of dapagliflozin was 
observed at week 12 in the treatment-naïve 
patients (an increase in urinary output of up 
to 470 mL/day above baseline compared with 
a 112 mL/day decrease in placebo). In those 
T2DM patients taking insulin plus oral insulin 
sensitizers there was an increase in urine output 
of up to 444 mL/day above baseline compared 
with  255  mL/day  with  placebo  (although 
the  difference  was  not  reported  as  being 
significant).40,41 Consistent with this observation, 
dapagliflozin appears to be associated with a 
mild reduction in mean blood pressure with no 
evidence of orthostatic hypotension.40,41
The long-term effects of dapagliflozin on renal 
function are as yet unknown, as are the effects of 
dapagliflozin when used in cases of compromised 
renal function or when coadministered with 
certain antihypertensive drug classes that may 
affect renal physiology. However, no clinically 
relevant changes in glomerular filtration rate have 
been reported with dapagliflozin treatment.39-41 
Owing to the inhibition of the cotransportation of 
sodium and glucose, dapagliflozin administration 
may result in an increase in urinary sodium. 
Acute transient increases in urine sodium have 
been observed with dapagliflozin treatment.39 
Median changes from baseline in urinary sodium 
excretion were +34.7, +40.2, and +48.0 mEq for 
the 5, 25, and 100 mg dapagliflozin treatment 
groups, and –15.1 mEq for the placebo group 
over the initial 24 hours. With continuing daily 
administration this increase in sodium excretion 
appeared to normalize, with median changes from 
baseline at day 13 of +1.8, +8.9, and –5.7 mEq for 
the 5, 25, and 100 mg dapagliflozin dose groups 
and +16.4 mEq for placebo. Despite the reported 
transient increase in urinary sodium excretion 
there is no evidence to suggest that this is reflected 
in any changes in serum sodium levels.39
Although dapagliflozin has been associated 
with  increases  in  urine  volume,  serum 
magnesium, serum phosphate, and serum uric 
acid these changes were still within normal 
physiological ranges and there was little evidence 
to suggest that dapagliflozin would produce 
clinically  significant  changes  in  electrolyte 
balance.
Because it was hypothesized that increasing 
urinary glucose may promote microbial growth, 
potential urinary tract infections (UTIs) and 
genital infections were carefully monitored. 
While  the  frequency  of  reported  UTIs  was 
similar between the dapagliflozin and placebo 
groups over the 12-week time period, symptoms 
suggestive of genital infections (in particular 
vulvocandidiasis) were reported more frequently 
in the groups administered dapagliflozin.40,41 
 In the 24-week studies, signs and symptoms 
suggestive of genital infection were reported in 
up to 13% of T2DM patients who were either 
treatment  naïve  or  who  were  inadequately 
controlled with metformin as compared with 
1.3% and 5% in the respective placebo groups.46,47 
No increased rate of discontinuation occurred as 
a result of these signs and symptoms suggestive 
of UTIs or genital infections.39,41-43,46-48 It is not Diabetes Ther (2010)  1(2):45-56. 53
known at this time how these observations in 
controlled trials will translate into infection 
rates in everyday clinical practice until more 
widespread experience is gained over a longer 
time frame.
Additional  data  are  necessary  to  fully 
elucidate  the  long-term  effects  of  glucose 
excretion  induced  by  dapagliflozin.  It  is 
noteworthy,  however,  that  people  with  a 
condition known as familial renal glucosuria 
(FRG), arising primarily from a mutation of the 
gene encoding for the SGLT2 protein (SLC5A2), 
live normal healthy lives, with no adverse 
events, despite the consistently high levels of 
urinary glucose.50 Experience with FRG is based 
on a very limited number of cases, and caution 
should be exercised when making comparisons 
with the general diabetic population. In these 
patients glucosuria can range from <1 to >150 
g/1.73 m2 per day. While FRG patients generally 
have few clinical complications polyuria and 
enuresis were observed in a single case study 
and were followed later by a slight delay in 
growth  and  pubertal  maturation.51  Other 
reported  complications  with  FRG  include 
episodes of dehydration and ketosis as well as 
urinary tract infections and natriuresis.50
However, unlike FRG, T2DM is associated 
with impaired immune responses, and patients 
with T2DM may have side effects relating to 
elevated urinary glucose levels. Furthermore, 
while glucose-induced diuresis does not appear 
to lead to dehydration in the majority of 
cases of FRG, the mild diuretic properties of 
dapagliflozin may require careful monitoring 
to ensure adequate fluid intake and warrants 
further investigation. One episode of renal 
failure did occur during treatment with 10 
mg dapagliflozin in a patient concomitantly 
being  treated  with  insulin  and  several 
antihypertensive  medications  (enalapril, 
carvedilol,  and  furosemide).  The  patient 
discontinued  dapagliflozin  as  a  result  of 
dehydration  and  prerenal  azotemia.  The 
condition was resolved with oral rehydration 
and  the  withholding  of  enalapril  and 
furosemide.41
SUMMARY AND THERAPEUTIC 
APPLICATIONS
T2DM is a progressive disease with a significant 
impact  on  patients,  society,  and  healthcare 
systems. The aim of treatment is to achieve 
near  normal  glycemia  in  order  to  prevent 
the development or slow the progression of 
microvascular  and  possibly  macrovascular 
complications. Currently available antidiabetes 
treatments have many limitations, including 
hypoglycemia  (sulfonylureas,  meglitinides, 
and  insulin),  weight  gain  (sulfonylureas, 
meglitinides,	TZDs,	and	insulin),	heart	failure	
(TZDs),	gastrointestinal	side	effects	(alpha-
glucosidase inhibitors, metformin), and the need 
for multiple injections and/or self-monitoring 
(insulin, amylin mimetics, and GLP-1 analogs). 
Furthermore,  due  to  the  progressive  nature 
of the disease, most patients will ultimately 
require  multiple  antidiabetes  treatments  to 
achieve glycemic targets. Hence, there is a need 
for new antidiabetes treatments that produce 
a sustainable impact on glycemic control with 
low risk for hypoglycemia and weight loss, 
and minimal need for self-monitoring. SGLT2 
inhibitors are a novel class of antidiabetes therapy 
that are taken orally, result in improvements 
in  glycemic  parameters  with  a  low  risk  for 
hypoglycemia, and are associated with weight 
loss. They have the potential to harness what 
has long been considered a manifestation of 
diabetes, glucosuria, and turn it into a therapeutic 
strategy. However, like other newer antidiabetes 
treatments, this class lacks long-term (including 
cardiovascular) safety data.54 Diabetes Ther (2010)  1(2):45-56.
With such a plethora of options to treat 
patients  with  T2DM,  the  decision  to  use  a 
particular drug, or combination of drugs, in a 
particular patient should be individualized based 
on the patient’s specific risk-benefit balance and 
not solely upon a drug’s perceived ability to 
lower HbA1c. Metformin (in addition to lifestyle 
changes) remains a well-established first-line 
treatment for patients with T2DM, due to good 
long-term safety data, lack of hypoglycemia or 
weight gain, and evidence for cardiovascular 
protection. However, as metformin does not 
halt the progression of the disease, patients 
with  T2DM  are  likely  to  need  additional 
antidiabetic medications administered alone 
or in combination with metformin. Should 
SGLT2 inhibitors, such as dapagliflozin, prove 
to have an acceptable safety profile they may 
have the potential to be administered alone 
or in combination with metformin or insulin. 
The lack of long-term (including cardiovascular) 
safety data and other outcome data may limit 
their use initially to specific/defined low-risk 
patient groups. 
CONCLUSION
In conclusion, dapagliflozin has the potential 
to be a useful addition to currently available 
antidiabetes treatments as it lowers fasting and 
postprandial glucose levels, improves glycemic 
control, and causes weight loss with a low risk 
of hypoglycemia. However, data regarding long-
term safety including urinary tract infection, 
genital infection, and cardiovascular safety are 
needed, and its place in the algorithm of T2DM 
management is still to be determined.    
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